Literature DB >> 24525750

Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells.

Yuttana Srinoulprasert1, Werner J Pichler.   

Abstract

BACKGROUND: The lymphocyte transformation test (LTT) is used for in vitro diagnosis of drug hypersensitivity reactions. While its specificity is over 90%, sensitivity is limited and depends on the type of reaction, drug and possibly time interval between the event and analysis. Removal of regulatory T cells (Treg/CD25(hi)) from in vitro stimulated cell cultures was previously reported to be a promising method to increase the sensitivity of proliferation tests.
OBJECTIVE: The aim of this investigation is to evaluate the effect of removal of regulatory T cells on the sensitivity of the LTT.
METHODS: Patients with well-documented drug hypersensitivity were recruited. Peripheral blood mononuclear cells, isolated CD3(+) and CD3(+) T cells depleted of the CD25(hi) fraction were used as effector cells in the LTT. Irrelevant drugs were also included to determine specificity. (3)H-thymidine incorporation was utilized as the detection system and results were expressed as a stimulation index (SI).
RESULTS: SIs of 7/11 LTTs were reduced after a mean time interval of 10.5 months (LTT 1 vs. LTT 2). Removal of the CD25(hi) fraction, which was FOXP3(+) and had a suppressive effect on drug-induced proliferation, resulted in an increased response to the relevant drugs. Sensitivity was increased from 25 to 82.35% with dramatically enhanced SI (2.05 to 6.02). Specificity was not affected.
CONCLUSION: Removal of Treg/CD25(hi) cells can increase the frequency and strengths of drug-specific proliferation without affecting specificity. This approach might be useful in certain drug hypersensitivity reactions with borderline responses or long time interval since the hypersensitivity reaction.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525750     DOI: 10.1159/000358491

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

Review 1.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

2.  Multiple drug sensitization syndrome: A distinct phenotype associated with unrecognized Mycoplasma pneumonia infection.

Authors:  Yumi Aoyama; Fumihisa Sawada; Eiichi Makino; Tetsuo Shiohara
Journal:  JAAD Case Rep       Date:  2017-07-18

3.  In Vitro Assays in Severe Cutaneous Adverse Drug Reactions: Are They Still Research Tools or Diagnostic Tests Already?

Authors:  Grzegorz Porebski
Journal:  Int J Mol Sci       Date:  2017-08-10       Impact factor: 5.923

Review 4.  An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.

Authors:  Chun-Bing Chen; Riichiro Abe; Ren-You Pan; Chuang-Wei Wang; Shuen-Iu Hung; Yi-Giien Tsai; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2018-02-13       Impact factor: 4.818

Review 5.  Antibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance.

Authors:  Inmaculada Doña; Marina Labella; Gádor Bogas; Rocío Sáenz de Santa María; María Salas; Adriana Ariza; María José Torres
Journal:  Antibiotics (Basel)       Date:  2022-08-03

6.  Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP.

Authors:  Chris Weir; Jamma Li; Richard Fulton; Suran L Fernando
Journal:  Allergy Asthma Clin Immunol       Date:  2022-10-09       Impact factor: 3.373

Review 7.  Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back.

Authors:  Rik Schrijvers; Liesbeth Gilissen; Anca Mirela Chiriac; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2015-09-03       Impact factor: 5.871

Review 8.  Years in Review: Recent Progress in Cellular Allergology.

Authors:  Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-03-09       Impact factor: 2.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.